KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Operations (2016 - 2025)

Sarepta Therapeutics has reported Cash from Operations over the past 15 years, most recently at 131206000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 131206000.0 for Q4 2025, up 42.54% from a year ago — trailing twelve months through Dec 2025 was 205479000.0 (changed 0.15% YoY), and the annual figure for FY2025 was 205479000.0, changed 0.15%.
  • Cash from Operations for Q4 2025 was 131206000.0 at Sarepta Therapeutics, up from 14585000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for SRPT hit a ceiling of 261337000.0 in Q2 2025 and a floor of 583437000.0 in Q1 2025.
  • Median Cash from Operations over the past 5 years was 81545500.0 (2022), compared with a mean of 84038850.0.
  • Biggest five-year swings in Cash from Operations: crashed 215.05% in 2022 and later surged 1649.01% in 2025.
  • Sarepta Therapeutics' Cash from Operations stood at 29326000.0 in 2021, then crashed by 215.05% to 92392000.0 in 2022, then soared by 40.84% to 54657000.0 in 2023, then surged by 268.41% to 92046000.0 in 2024, then skyrocketed by 42.54% to 131206000.0 in 2025.
  • The last three reported values for Cash from Operations were 131206000.0 (Q4 2025), 14585000.0 (Q3 2025), and 261337000.0 (Q2 2025) per Business Quant data.